Saratov JOURNAL of Medical and Scientific Research
Home

The use of linezolid and bedaquiline in patients with pulmonary tuberculosis in the postoperative period

Year: 2025, volume 21 Issue: №1 Pages: 62-67
Heading: Phthisiology Article type: Original article
Authors: Suleimanov S.Z., Sinitsyn M.V.
Organization: Pirogov Russian National Research Medical University, Moscow, Russia , National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Moscow, Russia
Summary:

Objective: to study the effectiveness of multidrug- and pre-extensively drug-resistant tuberculosis (ТВ) chemotherapy regimens with the inclusion of linezolid (Lzd) and bedaquiline (Bq) in operated patients for pulmonary ТВ. Material and methods. A non-randomized continuous single-center retrospective study of the data of 154 patients operated of NMRC PhPL for drug-resistant pulmonary tuberculosis in the period from 2018 to 2023 was performed. A comparative analysis of the effectiveness of chemotherapy regimens was carried out depending on the inclusion of new anti-tuberculosis drugs in it. Results. The proportion of adverse reactions in both observation groups when prescribing anti-tuberculosis drugs, excluding the use of Lzd and Bq, was comparable. Undesirable side effects were observed in 24.1% (n=21/87) in group 1 and in 25.4% (n=17/67) in group 2. The inclusion of Lzd and Bq in the postoperative chemotherapy regimen allowed a statistically significant reduction in the duration of the course to 38.5±2.1 weeks compared with the control group, where this period was 44.6±2.2 weeks. Thus, the timing of a favorable outcome was reduced by 6.1 weeks (p<0.05). Adverse reactions occurred in 24.1 % of patients treated with Lzd and Bq. Conclusion. The inclusion of Lzd and Bq in the multidrug- and pre-extensively drug-resistant ТВ chemotherapy regimen makes it possible to reduce the total duration of the course until a favorable outcome occurs.

Keywords: tuberculosis, surgical material, linezolid, drug resistance, bedaquiline, anti-tuberculosis therapy

Bibliography:
1. Vasileva IA, Sterlikov SA, Testov VV, et al. Resursy i de-jatelnost protivotuberkuljoznyh organizacij Rossijskoj Federacii v 2022-2023 gg. Moscow: RIO CNIIOIZ, 2024. 94 p.
2. Tuberculosis in adults. Clinical recommendations. Russian Society of Phthisiologists. Moscow, 2022. 151 p.
3. Vasilyeva IA, Belilovsky ЕМ, Borisov SE, et al. Incidence, mortality and prevalence as indicators of tuberculosis burden in WHO regions, countries of the world and the Russian Federation. Part 1. Tuberculosis incidence and prevalence. Tuberculosis and Lung Diseases. 2017;95 (6):9-21. DOI: 10.21292/2075-1230-2017-95-6-9-21
4. Wallis RS, Maeurer М, Mwaba Р, et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016; 16 (4):e34-46. DOI:10.1016/S1473-3099(16)00070-0
5. Tiberi S, Mufioz-Torrico M, Duarte R, et al. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018;24(2):86-98. DOI:10.1016/j.rppnen.2017.10.009
6. Lee M, Cho SN, Barry CE, et al. Linezolid for XDR-TB-final study outcomes. N Engl J Med. 2015;373 (3):290-1. DOI:10.1056/NEJMd 500286
7. Ruzanov DJu, Skrjagina EM, Bujnevich IV, et al. Novye shemy i novye preparaty v lechenii tuberkuleza: shagaem v nogu? Kliniceskaa Mikrobiologia i Antimikrobnaa Himioterapia. 2021 ;23 (1):27-42. DOI:10.36488/стас.2021.1.27-42
8. Zhang S, Chen J, Cui P, et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob Agents Chemother. 2016;60 (4):2542-4. DOI:10.1128/AAC.02941-15
9. Zhang Z, Pang Y, Wang Y, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents. 2014;43 (3):231-5. DOI:10.1016/j.ijantimicag.2013.12.007
10. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007;51 (4):1534-6. DOI:10.1128/AAC.01113-06
11. Peretokina IV, Krylova LY, Antonova OV, et al. Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates. J Infect. 2020;80 (5):527-35. DOM 0.1016/j.jinf. 2020.01.007
12. Belousova KV, Umpeleva TV, Eremeeva Nl, et al. Drug susceptibility and genotype affinity of Mycobacterium tuberculosis isolated from surgical specimens of pulmonary tuberculosis patients. Tuberculosis and Lung Diseases. 2019;97 (7):11-7. DOI:10.21292/2075-1230-2019-97-7-11-17
13. Common Terminology Criteria for Adverse Events (CT-CAE), version 5.0. National Cancer Institute, 2017. URL: https:// ctep.cancer.gov/protocoldevelopment/electronic_applica-tions/docs/ctcae_v5_quick_reference_5x7.pdf (1 Dec 2024).
14. Division of microbiology and infection diseases (DMID) adult toxicity table — DRAFT. Microbiology and infectious diseases clinical research policies, guidance, and tools. National institute of allergy and Infectious diseases. Bethesda, 2007. URL: https://www.niaid.nih.gov/LabsAndResources/resources/DMID-ClinRsrch/Documes/dmidadulttox.pdf (12 Dec 2024).
15. Diacon AH, Pym A, Grobusch M, et al. The diarylquino-line TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360 (23):2397-405. DOI:10.1056/NEJMoa0808427
16. Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaqui-line-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387 (9):810-23. DOI:10.1056/NEJ-Moa2119430
17. Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47 (2):564-74. DOM 0.1183/13993003.00724-2015
18. Konovalova NM, Odinets VS, Vasilenko Tl, et al. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple and extensive drug resistance. Tuberculosis and Lung Diseases. 2017;95 (12):49-53. DOI: 10.21292/2075-1230-2017-95-12-49-53

AttachmentSize
2025_01_062-067.pdf315.88 KB
All articles of the authors: Suleimanov S.Z., Sinitsyn M.V.

No votes yet